Kenvue Stock Rebounds After Trump’s Tylenol-Autism Comments

Kenvue shares staged a partial recovery Tuesday, clawing back nearly 60% of Monday's 7% plunge triggered by former President Trump's remarks about Tylenol and autism risk. The consumer health stock had tumbled as traders priced in potential regulatory risks after TRUMP suggested pregnant women avoid acetaminophen.

Market participants appear to have overestimated the immediate policy implications. While Trump called Tylenol use during pregnancy "not good," accompanying administration materials noted insufficient evidence proving causation. This regulatory ambiguity created a classic buy-the-dip opportunity for event-driven traders.

The episode highlights how political rhetoric can temporarily distort healthcare valuations, particularly for consumer brands with regulatory exposure. Kenvue's volatility underscores the market's hypersensitivity to drug safety narratives, even when scientific consensus remains unresolved.